Sort
78,016 grants matching “breast cancer”
Developmental Funds
$535,817Jennifer A Pietenpol · Vanderbilt University · P30 · FY2010 · CA
The DARC side of Breast Cancer Disparities - African Ancestry and Cancer- Related Immune Response
$535,758Melissa B Davis · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA
Utah Population Database (UPDB)
$535,755Nicola J Camp · University Of Utah · P30 · FY2024 · CA
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$535,736Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2025 · CA
MOLECULAR MECHANISMS OF IGFBP-3 REGULATION ON GRP78-INDUCED ANTIESTROGEN RESISTANCE TO BREAST CANCER
$535,733Virginia Commonwealth University · · FY2009 · Department of Defense
Transcription Dynamics in Single Cells
$535,701Daniel Larson · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Estimating Overdiagnosis in Cancer Screening Studies
$535,700Ruth D Etzioni · Fred Hutchinson Cancer Research Center · R01 · FY2016 · CA
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
$535,666Philip O. Livingston · Mabvax Therapeutics, Inc. · R42 · FY2010 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$535,638Wei R. Chen · University Of Oklahoma · R01 · FY2022 · CA
Copper-depleting nanotheranostics for treating triple negative breast cancer
$535,635Jianghong Rao · Stanford University · R01 · FY2021 · CA
Copper-depleting nanotheranostics for treating triple negative breast cancer
$535,635Jianghong Rao · Stanford University · R01 · FY2019 · CA
Copper-depleting nanotheranostics for treating triple negative breast cancer
$535,635Jianghong Rao · Stanford University · R01 · FY2020 · CA
Local Therapy of Gliomas Using a Novel BCNU Formulation
$535,608Direct Therapeutics, Inc. · R44 · FY2004 · CA
Long Term Health Outcomes in Breast Cancer Survivors
$535,523Bette J Caan · Kaiser Foundation Research Institute · R01 · FY2006 · CA
Computational Model of Aberrant Signaling Networks in Cancer
$535,471Paul T Spellman · University Of Calif-Lawrenc Berkeley Lab · U54 · FY2007 · CA
Targeting HER2-low breast cancer with 17p loss
$535,448Xiongbin Lu · Indiana University Indianapolis · R01 · FY2021 · CA
YIN AND YANG OF HEPARANASE IN BREAST CANCER INITIATION
$535,437Rush University Medical Center · · FY2011 · Department of Defense
Copper-mediated metabolic reprogramming and ECM alterations in TNBC metastasis
$535,436Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Validation and translation of a non-invasive, MR-guided breast cancer therapy
$535,426Allison Payne · University Of Utah · R37 · FY2023 · CA
Engineered Nanoformulation for Immune-modulation in Cancer
$535,400Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2024 · CA
Human Breast Cancer Stem Cell Surrogates
$535,374Wendy A Woodward · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
Validating Molecular Signature Risk Models of NSCLC
$535,358David H Harpole · Duke University · R01 · FY2007 · CA
Cross-species network approach to predict epistatic cancer susceptibility genes
$535,355Amanda G Paulovich · Fred Hutchinson Cancer Research Center · R01 · FY2012 · CA
EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER
$535,343David McCormick · Iit Research Institute · N01 · FY2021 · CA
Satisfaction of Search in Breast Cancer Detection
$535,304Claudia R Mello-Thoms · University Of Iowa · R01 · FY2025 · CA